The Global Prolife Alliance (GPA) has called for a halt on the continuing use of the MenAfriVac meningitis A vaccine after the disturbing news of paralysis of children vaccinated. On December 20, 2012, a vaccination tragedy hit the small village of Gouro, located in Northern Chad, in Sub- Saharan Africa. According to the newspaper La Voix, out of five hundred at least 40 (8%) of them between the ages of 7 and 18 years became paralyzed. The children presented with symptoms of hallucinations and convulsions. http://vactruth.com/2013/01/06/paralyzed-after-meningitis- vaccine/ Further research into the vaccine MenAfriVac revealed that, the vaccine was manufactured by Serum Institute of India Limited sponsored by Bill and Melinda Gates Foundation. According to the partners in the Meningitis Vaccine Project (MVP), PATH, GAVI, UNICEF, CDC, WHO and Bill and Melinda Gates Foundation, it is the first vaccine to gain approval to travel outside the cold chain, meaning that the vaccine can be transported without refrigeration or ice packs for up to four days: “The meningitis A vaccine known as MenAfriVac®, created to meet the needs of Africa’s meningitis belt, can now be kept in a controlled temperature chain (CTC) at temperatures of up to 40°C for up to four days, a decision that could help increase campaign efficiency and coverage and save funds normally spent maintaining the challenging cold chain during the “last mile” of vaccine delivery.” http://www.meningvax.org/files/PressReleasePATH_WHO_MVP14Nov2012.En.pdf (originally published by now not found) The manufacturer Serum Institute of India Ltd states clearly that storage and transport should be maintained in cold chain: MenAfriVac should be stored and transported between 2-8oC. Protect from light. The diluent should be stored at 25°C. It is recommended to protect the reconstituted vaccine from direct sunlight. Do not exceed the expiry date stated on the external packaging. Immediately prior to reconstitution the vaccine is stable and can be used when exposed upto 40oC for period of 4 days provided the vaccine has not reached its expiry date and  the vaccine vial monitor has not reached the discard point.http://www.seruminstitute.com/content/products/product_menafrivac.htm

1. PRESS RELEASE
The Bill Gates MenAfriVac Gouro Tragedy: 40 Paralyzed
Children. Calls for a Halt!
Paralyzed Victims of the MenAfriVac in Gouro, Chad.
http://vactruth.com/2013/01/06/paralyzed-after-meningitis-vaccine/
Christian England, January, 6th 2013.
The Global Prolife Alliance (GPA) has called for a halt on the continuing use of the MenAfriVac
meningitis A vaccine after the disturbing news of paralysis of children vaccinated. On December
20, 2012, a vaccination tragedy hit the small village of Gouro, located in Northern Chad, in Sub-
Saharan Africa. According to the newspaper La Voix, out of five hundred at least 40 (8%) of them
between the ages of 7 and 18 years became paralyzed. The children presented with symptoms of
hallucinations and convulsions. http://vactruth.com/2013/01/06/paralyzed-after-meningitis-vaccine/
Further research into the vaccine MenAfriVac revealed that, the vaccine was manufactured by
Serum Institute of India Limited sponsored by Bill and Melinda Gates Foundation. According to
the partners in the Meningitis Vaccine Project (MVP), PATH, GAVI, UNICEF, CDC, WHO and
Bill and Melinda Gates Foundation, it is the first vaccine to gain approval to travel outside the
cold chain, meaning that the vaccine can be transported without refrigeration or ice packs for up
to four days:
“The meningitis A vaccine known as MenAfriVac®, created to meet the needs of
Africa’s meningitis belt, can now be kept in a controlled temperature chain
(CTC) at temperatures of up to 40°C for up to four days, a decision that could
help increase campaign efficiency and coverage and save funds normally spent
maintaining the challenging cold chain during the “last mile” of vaccine
delivery.” http://www.meningvax.org/files/PressReleasePATH_WHO_MVP14Nov2012.En.pdf
(originally published by now not found)
The manufacturer Serum Institute of India Ltd states clearly that storage and transport should
be maintained in cold chain:
MenAfriVac should be stored and transported between 2-8ºC. Protect from light. The
diluent should be stored at 25°C. It is recommended to protect the reconstituted vaccine
from direct sunlight. Do not exceed the expiry date stated on the external packaging.
Immediately prior to reconstitution the vaccine is stable and can be used when exposed
upto 40ºC for period of 4 days provided the vaccine has not reached its expiry date and

2. the vaccine vial monitor has not reached the discard
point.http://www.seruminstitute.com/content/products/product_menafrivac.htm
Excepts of the report from a meeting which took place in October
2012 between the World Health Organization’s Immunizations, Vaccines and
Biologicals group and the Immunization Practices Advisory Committee (IPAC), shows that the
vaccine would not be endorsed until 2013, at the earliest:
… This is the final review of the document by IPAC prior to the planned field
testing during the MenAfriVac® campaign in Benin in November 2012, where
one district will use the vaccine in a CTC. After the field testing has been
conducted, the revised final guidance document will come back to IPAC for
endorsement in 2013.” http://www.path.org/files/TS-optimize-newsletter-apr12.pdf
This suggests that, the safety standards for the MenAfriVac did not meet the WHO certification
standards for the stated application outside the cold chain at the time the vaccine was
administered in Gouro, Chad. The result was a devastating health consequence for the children
in Gouro, Chad and the very high risks it poses for 16 million Nigerians and millions more across
Sub-Saharan Africa if not used in the prescribed manner. The only logical safety precaution that
applies to use of all drugs and vaccines according to good practices recognised in all countries is
to HALT the use of the vaccine for now. To carry out a comprehensive review of the safety of the
vaccine based on adverse effects reporting in a registry.
The GPA calls on the Governments of Sub-Saharan African Countries, the Bill and Melinda
Gates Foundation and all other partners in the Meningitis Vaccine Project to set up a Fund in
each country where the vaccine was administered that would be used for Meningitis Vaccine
Adverse Effects Monitoring Network across Africa, and Victims Treatment and Compensation
Fund as a result of this unfolding tragedy. Victims are also advised to seek compensation in the
courts in their countries.
Furthermore, the GPA warns African Leaders that there is an on-going GRAND CONSPIRACY
with yet to unfold health consequences of the continuing misuse of vaccines which could one-day
result in a TOTAL FINAL SOLUTION TYPE HOLOCAUST of all Black Africans! Just imagine if
there is a car bomb killing two people in Abuja, it will be on CNN, BBC and Aljazeera, but the
paralysis of 40 prior healthy children after MenAfriVac vaccination was not reported by the
major networks. Kept Secret and the Truth left on the Faces of Suffering Crippled African
Children, abandoned by their corrupt government and their parents left helpless. This will tell
you the extent of this GRAND CONSPIRACY of silence to cover up the TRUTH!
The GPA holds accountable the Governments of Sub-Saharan African Countries, G7 countries,
UNICEF, Bill and Melinda Gates Foundation and WHO for any resulting adverse health
consequences inflicted on African Children as a result of the use the MenAfriVac vaccine.
The GPA maintains that the vaccination for meningitis using the MenAfriVac must be halted.
Signed by:
Academician Prince Dr Philip Njemanze MD, Chairman, Global Prolife Alliance (GPA) for
Council.